Saturday, 07 December 2019

AbGenomics gets go ahead for phase II trial

20 August 2012 | News | By BioSpectrum Bureau

AbGenomics gets go ahead for phase II trial

AbGenomics gets nod for phase II trial

AbGenomics gets nod for phase II trial

Singapore: US-based firm AbGenomics International, which has subsidiaries in Taiwan and the Netherlands, has obtained agreement from US Food and Drug Administration (FDA) for its proposed plans for a phase II clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H.

Our antibody demonstrated a great safety profile in preclinical safety and phase I clinical trial studies in both psoriasis patients and healthy volunteers. In SRD phase I psoriasis patient study, a clear biological or pharmacological effect consistent with the proposed mechanism of action of AbG's antibody was demonstrated in patients. The current phase II clinical trial of AbGn-168H will be a multicenter, placebo-controlled, double-blind trial.

The primary objective of the study is to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect in psoriatic patients. Additional clinical trials for type-I diabetes, Crohn's and other autoimmune diseases are under evaluation.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls